598 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
152. YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia
153. Effects of Pravastatin on Human Placenta, Endothelium, and Women With Severe Preeclampsia
154. Proton Pump Inhibitors quench the pathophysiological characteristics of preeclampsia in both human and mouse models and represent an exciting novel candidate therapeutic
155. Human HtrA4 Expression Is Restricted to the Placenta, Is Significantly Up-Regulated in Early-Onset Preeclampsia, and High Levels of HtrA4 Cause Endothelial Dysfunction
156. Paternal obesity in a rodent model affects placental gene expression in a sex-specific manner
157. Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)–Like 2/Heme Oxygenase-1 Pathway, Reduces Soluble fms–Like Tyrosine Kinase-1, and Quenches Endothelial Dysfunction
158. [273-POS]
159. [28-OR]
160. [261-POS]
161. [44-OR]
162. [6-OR]
163. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sFlt-1 and soluble endoglin
164. Epidermal Growth Factor Rescues Endothelial Dysfunction in Primary Human Tissues In Vitro.
165. Maternal plasma concentrations of the placental specific sFLT-1 variant, sFLT-1 e15a, in fetal growth restriction and preeclampsia.
166. Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion, Decrease Hypertension, and Rescue Endothelial Dysfunction.
167. Proton Pump inhibitors significantly quench pathophysiological characteristics of preeclampsia in primary placental and endothelial models: A novel candidate therapeutic
168. HO-1 expression is not reduced in preeclamptic placenta, and does not regulate sFlt-1 or soluble endoglin secretion in either primary trophoblast or endothelial cells
169. A Bioplex Analysis of Cytokines and Chemokines in First Trimester Maternal Plasma to Screen for Predictors of Miscarriage
170. PAPPA2 is increased in severe early onset pre-eclampsia and upregulated with hypoxia
171. Effects of Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, on Human Placental Cell Growth
172. Circulating Chemerin Is Elevated in Women With Preeclampsia
173. Plasma MIC-1 and PAPP-A Levels Are Decreased among Women Presenting to an Early Pregnancy Assessment Unit, Have Fetal Viability Confirmed but Later Miscarry
174. Combination methotrexate and gefitinib (EGFR inhibitor) as a novel therapeutic to medically treat ectopic pregnancies: preclinical studies and human trials
175. Generation and testing of an ELISA that detects the newly discovered primate and placental specific sFlt variant (sFlt1-e15a)
176. Maternal Serum Macrophage Inhibitory Cytokine-1 as a Biomarker for Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
177. Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study
178. Placental Specific mRNA in the Maternal Circulation Are Globally Dysregulated in Pregnancies Complicated by Fetal Growth Restriction
179. Targeted Nanoparticle Delivery of Doxorubicin Into Placental Tissues to Treat Ectopic Pregnancies
180. A comparison of sample collection methods for quantifying cell-free fetal neurodevelopment transcripts in amniotic fluid.
181. Evaluation of ADAM-12 as a Diagnostic Biomarker of Ectopic Pregnancy in Women with a Pregnancy of Unknown Location
182. MMP-15 Is Upregulated in Preeclampsia, but Does Not Cleave Endoglin to Produce Soluble Endoglin
183. Identification of Label-Retaining Perivascular Cells in a Mouse Model of Endometrial Decidualization, Breakdown, and Repair1
184. Serum Concentrations of Soluble Flt-1 Are Decreased among Women with a Viable Fetus and No Symptoms of Miscarriage Destined for Pregnancy Loss
185. [44-OR]: Statins reduce soluble Flt1, and quench endothelial dysfunction in primary human tissues, but increase soluble endoglin release
186. [28-OR]: The newly described primate and placental specific sFlt1 isoform – e15a is biologically active and antagonises VEGF
187. [6-OR]: Proton pump inhibitors for treatment of preeclampsia
188. [273-POS]: Sulfasalazine reduces the toxins of preeclampsia soluble Flt1 and soluble endoglin and quenches endothelial dysfunction in primary human tissues: A novel potential therapeutic
189. [261-POS]: Heme oxygenase-1 is not reduced in pre-eclampsia and does not regulate sFlt-1 or soluble endoglin production
190. Reepithelialization of the Uterine Surface Arises from Endometrial Glands: Evidence from a Functional Mouse Model of Breakdown and Repair
191. A New Role for Activin in Endometrial Repair after Menses
192. Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives
193. A New Role for Activin in Endometrial Restoration Following Menses.
194. Claudin-11 expression and localisation is regulated by androgens in rat Sertoli cells in vitro
195. The long-term actions of etonogestrel and levonorgestrel on decidualized and non-decidualized endometrium in a mouse model mimic some effects of progestogen-only contraceptives in women
196. Sofalcone Upregulates the Nuclear Factor (Erythroid-Derived 2)-Like 2/Heme Oxygenase-1 Pathway, Reduces Soluble fms-Like Tyrosine Kinase-1, and Quenches Endothelial Dysfunction.
197. Neutrophil depletion retards endometrial repair in a mouse model
198. Complex expression patterns support potential roles for maternally derived activins in the establishment of pregnancy in mouse
199. Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs.
200. Corin, an enzyme with a putative role in spiral artery remodeling, is up-regulated in late secretory endometrium and first trimester decidua.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.